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Gene transfer systems based on lentiviruses have emerged as promising gene delivery vehicles for human gene therapy
due to their ability to efficiently transduce nondividing target cells. Both primate and nonprimate lentiviruses have been used
for construction of lentiviral vectors. An early generation of gene transfer system based on bovine immunodeficiency virus
(BIV) has been developed (R. D. Berkowitz, H. Ilves, W. Y. Lin, K. Eckert, A. Coward, S. Tamaki, G. Veres, and I. Plavec, 2001,
J. Virol. 75, 3371–3382). In this study, we mapped the BIV Rev response element (RRE) to 312 bp of the Env coding region.
Furthermore, we compared transduction efficiencies of vectors containing different portions of the BIV Gag coding region
and found that the first 104 bp of gag contains a functional part of the BIV packaging signal. These findings enabled the
generation of a minimal BIV-based lentiviral vector. The minimal transfer vector construct consists of a self-inactivating long
terminal repeats (LTR), minimal packaging sequence, putative central polypurine tract, minimal RRE, an internal promoter
driving the gene of interest, and a woodchuck hepatitis posttranscriptional regulatory element. In addition, we constructed
a BIV packaging construct containing gag/pol, minimal Rev/RRE, and the accessory gene vpy. The regulatory gene tat and
the accessory genes vif and vpw have been inactivated or truncated. The current system has significantly reduced regions
of homologies between the transfer vector and the packaging constructs. The vectors generated from this system achieved
a titer of greater than 1  106 transducing units per milliliter and are fully functional as indicated by their ability to efficiently
transduce both dividing and nondividing cells. These modifications should provide improved safety features for the BIV-basedINTRODUCTION
Various viral vectors have been explored as vehicles
to deliver therapeutic genes for human gene therapy.
Murine leukemia virus (MLV), adenovirus, and adenoas-
sociated virus (AAV) based vectors have been widely
used for such purposes. All these vector systems have
their strengths and weaknesses. MLV-based vectors
have been proven safe for human gene therapy yet suffer
from an inability to transduce nondividing cells, which
are often the therapeutic targets in vivo (Miller et al.,
1990; Roe et al., 1993; Lewis and Emerman, 1994; Liu et
al., 1996; Uchida et al., 1998). Human adenovirus based
vectors are capable of efficiently transducing a variety of
nondividing target cells. However, a strong host immune
reaction and transient gene expression have limited the
applications of the most commonly used vectors. AAV-
based vectors have shown promise in preclinical and
clinical trials; however, packaging capacity is a limita-
tion.
Lentivirus-based gene transfer systems represent a
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10promising gene delivery technology due to their ability to
efficiently transduce a variety of nondividing target cells
in vitro and in vivo (Poznansky et al., 1991; Lewis et al.,
1992; Naldini et al., 1996a,b; Blomer et al., 1997; Kafri et
al., 1997; Miyoshi et al., 1997; Gallichan et al., 1998;
Douglas et al., 1999; Galileo et al., 1999). In addition,
lentiviral vector-mediated gene expression does not re-
quire de novo synthesis of viral proteins, reducing the
potential elimination of target cells by the host immune
system. The vector system has shown utility in preclini-
cal animal models of Parkinson’s disease and ocular
diseases (Takahashi et al., 1999; Deglon et al., 2000;
Kordower et al., 2000). However, the lentiviral systems
with the most promising results have been those based
on human immunodeficiency virus (HIV), the causative
agent of AIDS. Several animal lentivirus-based gene
transfer systems have been developed, providing alter-
natives to HIV-based vectors (Olsen, 1998; Poeschla et
al., 1998; Mitrophanous et al., 1999; Curran et al., 2000;
Mangeot et al., 2000; Berkowitz et al., 2001a,b).
Bovine immunodeficiency virus (BIV) is a lentivirus that
infects a large number of cattle (Garvey et al., 1990;
Gonda et al., 1994; St. Cyrcoats et al., 1994). However, the
significance of natural BIV infections to the health ofgene transfer system. © 2002 Elsevier Science (USA)
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herds has not been clearly established (Gonda et al.,
1994). Interestingly, BIV causes acquired immune dys-irus; pa
function in experimentally infected rabbits (Kalvatchev et
al., 1995; Walder et al., 2001). In addition to its three
structural genes (gag, pol, and env), BIV has two regu-
latory genes (tat, rev) and three accessory genes (vif,
vpw, and vpy) in the central region. Also, it has been
suggested that an additional open reading frame may
exist at the end of env, which encodes a fourth accessory
gene, tmx, in the same frame as env (Garvey et al., 1990;
Oberste et al., 1993). Unlike HIV, BIV has not been inten-
sively studied. The biological functions of the BIV acces-
sory genes are unknown. Furthermore, locations of some
important BIV elements such as the packaging signal
sequence and Rev response element (RRE) have not
been identified. There is no significant sequence homol-
ogy between BIV and other lentiviruses except for the
reverse transcriptase coding sequence. Therefore, it pre-
sents a significant challenge to derive an advanced gene
transfer system from this virus. An early generation gene
transfer system based on bovine immunodeficiency virus
has been developed (Berkowitz et al., 2001b). In this
study, we mapped the location of the BIV packaging
signal and RRE and generated a minimal transfer vector
construct. We also modified the early generation pack-
aging construct pBH2 (Berkowitz et al., 2001b) by includ-
ing the identified RRE and blocking expression of the
accessory genes vif, vpw, and the regulatory gene tat.
The BIV vectors produced with this system achieve a titer
greater than 1  106 transducing units per milliliter and
are fully functional as indicated by their efficient trans-
duction of both dividing and nondividing cell lines, as
well as human primary cells.
RESULTS
Minimal requirement of BIV gag sequence for
packaging
It has been shown in HIV that approximately 50 nucle-
otides between the major splice donor site (MSD) and
the gag initiation codon as well as the first 40 nucleo-
tides of gag are critical for efficient RNA packaging
(Lever et al., 1989; Aldovini and Young, 1990; Clavel and
Orenstein, 1990; Luban and Goff, 1994). The location of
the BIV packaging sequence has not been identified. The
early generation BIV vector pBS4MGppt had 509 bp of
gag sequence remaining, which contained the putative
packaging sequence (Berkowitz et al., 2001b). To reduce
the sequence homology between the transfer vector and
our Gag/Pol expression packaging construct, we deter-
mined the minimal amounts of gag sequence required to
preserve the packaging function. We made a series of
deletions to the Gag-coding sequence from the 3 end of
the 509-bp gag sequence in pBS4MGppt, generating four
constructs with 212 bp gag (pBIVminivec), 28 bp gag
(pBv28), 54 bp gag (pBv54), and 104 bp gag (pBv104).
Lentiviral vectors were generated from each of these four
vector constructs by cotransfection with packaging and
VSV-G expression constructs and compared with the
parental vector pBSV4MGppt (Berkowitz et al., 2001b).
The number of vector particles were normalized by re-
verse transcriptase (RT) activity and equal amounts of
RT-containing vector supernatants were used to trans-
duce Cf2Th cells. As shown in Fig. 1, the vectors with
either 212 or 104 bp of gag sequence achieved transduc-
tion efficiencies equivalent to the parental construct con-
taining 509 bp of Gag-coding sequence. Thus the 405-bp
gag deletion did not affect the putative packaging se-
quence (compare Figs. 1C and 1F to 1B). However, fur-
FIG. 1. The first 104 bp of gag sequence is important for BIV vector
packaging. The same number of Cf2Th cells were transduced with
Mock (A); or equal amounts of RT containing vectors pBS4MGppt
(containing 509-bp gag, B); pBIVminivec (containing 212-bp gag, C),
pBv28 (containing 28-bp gag, D), pBv54 (containing 54-bp gag, D),
pBv104 (containing 104-bp gag, E). eGFP expression was measured by
flow cytometry analysis 48 h posttransduction. The number in the
panels represents the percentage of GFP-positive cells. The experi-
ment was repeated three times with similar results.
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ther deletion of the gag sequence resulted in defective
vector particles, as indicated by the lack of transduction
with vectors containing either 28 or 54 bp of gag (Figs.
1D and 1E). While the precise location and the second-
ary structure of the packaging signal sequence within
the BIV vectors still remains unclear, the results suggest
that the 5 untranslated region (UTR) and the first 104 bp
of Gag coding sequence are sufficient for packaging BIV
vector RNA.
Identification of the BIV Rev response element
In HIV and other lentiviruses, Rev is responsible for
nuclear export of unspliced viral genomic RNA and singly
spliced mRNA by binding to the Rev response element.
The BIV RRE sequence had not been identified. The early
generation BIV vector pBC4MGppt contained the puta-
tive RRE sequence in a 778-bp envelope coding region
(Berkowitz et al., 2001b). Exclusion of this 778-bp putative
RRE sequence resulted in defective vector particles (data
not shown). To reduce the sequence homology between
the transfer vector and the Gag/Pol packaging construct,
we accurately mapped the location of the RRE within
these 778 bp. We created seven different constructs that
incorporated different regions of the putative RRE (Table
1). Each of the seven constructs was transfected into
293T cells together with the BIV packaging construct
pBH2M2 (see Materials and Methods) and the VSV-G
expression plasmid. Forty-eight hours posttransfection,
viral supernatants were harvested. Each supernatant
was normalized by the amount of reverse transcriptase
activity, and the same amount of RT-containing vector
supernatant was used to transduce 293T cells. Of the
seven constructs created, only vectors generated from
pBvRRE6 and pBvRRE7 (containing RRE6 and RRE7)
transduced cells as efficiently as vectors produced by
the parental construct containing the full 778-bp RRE
sequence (Table 1). These data suggest that the se-
quence containing the RRE can be narrowed down to
approximately 300 bp (Fig. 2A). RRE function is known to
be orientation specific. To further verify that the 300-bp
sequence was functioning as an RRE, we inserted it into
the vector in reverse orientation. As expected (Fig. 2B), in
reverse orientation, sequence was nonfunctional. Finally,
vector particle production is Rev-dependent; removal of
rev from the packaging construct diminished vector par-
ticle yield as determined by RT levels (data not shown).
With the mapping of packaging sequence and RRE, a
minimal BIV transfer vector construct was generated
(Fig. 3). Starting from the 5 end, the minimal transfer
vector construct contains the following: 5 long terminal
repeats (LTR) with a CMV immediate-early enhancer-
promoter replacing U3, an intact UTR between LTR and
gag coding region, 212- or 104-bp gag coding region,
RRE6, an internal promoter driving a transgene, 3 poly-
purine tract, 3 LTR with a 332-bp deletion in U3, and a
40-bp SV40 late polyadenylation signal upstream en-
hancer element inserted in the place of the U3 deletion
(Carswell and Alwine, 1989; Berkowitz et al., 2001b). In
addition, the woodchuck hepatitis virus posttranscrip-
tional regulatory element (PRE) was incorporated into the
TABLE 1
Mapping of BIV RRE
Construct Base pairs Primer sequence Transduction efficiency
Positive control pBvG 6783–7561 n/a 100%
1. pBvRRE1 6783–7030 5 ggcgaattcgatctaggaaaaaattttccg-3
3 ggaagatctccacaaacccatagctgg-5
1%
2. pBvRRE2 7005–7290 5 cccgaattcaaaggtccccagc-3
3 ggaagatctctctatggtgtaggac-5
65%
3. pBVRRE3 7288–7561 5 ccggaattcgagtttcatacttggag-3
3 ggaagatcttgcactaaatggtc-5
9%
4. pBvRRE4 6908–7181 5 ccggaattccctaatactatgcc-3
3 ggaagatctcttagccgtcgtgtgc-5
38%
5. pBvRRE5 7192–7431 5 ggcgaattcgggttgtgcaaaatgtg-3
3 cctagatctcattccaagttttgct-5
3%
6. pBvRRE6 6992–7303 5 ccggaattcgtggattcttgtaaagg-3
3 ggaagatctctccaagtatgaaactc-5
106%
7. pBvRRE7 7048–7345 5 ccagaattccaccaccatccctcc-3
3 ggaagatctcaaccaaagaatact-5
98%
Note. Seven different constructs that incorporated different regions of the putative RRE. All seven constructs were individually transfected into 293T
cells together with the BIV packaging construct, pBH2M2, and the VSV-G expression plasmid. Forty-eight hours posttransfection viral supernatant was
harvested. These supernatants were normalized by the amount of reverse transcriptase (RT) activity and the same amount of RT-containing vector
supernatant was used to transduce 293T cells. Of the seven constructs created, only vectors generated from pBvRRE6 and pBvRRE7 (containing RRE6
and RRE7) transduced cells as efficiently as vectors produced by the parental construct containing the full 778-bp RRE. The bp numbers for each RRE
correspond to the nucleotide position in BIV genomic RNA sequence isolate 127 (Garvey et al., 1990).
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BIV transfer vector immediately downstream eGFP cod-
ing sequence. The PRE has been shown to be able to
enhance transgene expression in the context of retroviral
and lentiviral vectors (Zufferey et al., 1999). The PRE
element increased eGFP expression by three- to fivefold
in the context of BIV vectors (data not shown). A putative
BIV central purine tract was also included in the vector
(Berkowitz et al., 2001b) (Fig. 3).
FIG. 2. (A) The 312-bp minimal BIV RRE sequence located within the envelope gene. This sequence is required and sufficient to support nuclear
export. (B) Effect of orientation on RRE function. 293T cells were transduced with Mock (a), equal amounts of RT containing vectors generated by either
pBv104 (b) or pBv104ERR (with RRE at reverse orientation) (c). Forty-eight hours posttransduction, the transduced cells were analyzed for eGFP
expression by flow cytometry. The number in the panels represents the percentage of eGFP-positive cells. The experiment was repeated three times
with similar results.
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Modification of the BIV packaging construct
The packaging construct was derived from pBH2,
which has previously been described (Berkowitz et al.,
2001b). In addition to gag, pol, and env, BIV has two
regulatory genes, tat and rev, and four predicted acces-
sory genes, vif, vpw, vpy, and tmx. HIV has four accessory
genes, vif, vpr, vpu, and nef, some of which play impor-
tant roles for viral pathogenesis (Kestler et al., 1991;
Trono, 1995) but are dispensable for the HIV vector-
mediated gene transfer into nondividing cells (Parolin et
al., 1994; Reiser et al., 1996; Zufferey et al., 1997). We
generated a packaging construct, pBH2M2RRE6, which
has the tat ATG start site mutated to a stop codon, and
the vif and vpw open reading frames disrupted by stop
codons. Moreover, we also deleted 50 bp of untranslated
leader sequence upstream of the major splice donor site
(Fig. 3). These mutations were confirmed by direct DNA
sequencing. In addition, the minimal RRE6 was intro-
duced into the construct between the two exons coding
for Rev.
Titer of minimal BIV vectors
We examined the titer of the BIV vectors produced
from 293T cells cotransfected with the transfer vector,
pBIVminvec, the packaging construct, pB2M2RRE6, and
the VSV-G expression construct. Cf2Th cells (4  105)
were transduced with different amounts of vectors en-
coding eGFP. Forty-eight hours posttransduction, 18.5%
of cells scored positive for eGFP expression in the sam-
ple containing 50 l of vector supernatant giving a rela-
tive vector titer of 1.5  106 transducing units (T.U.) per
milliliter (Fig. 4). It should be noted that the titer scored by
eGFP expression is not absolutely linear with the vector
input.
FIG. 3. Schematic representation of BIV-based gene transfer system. The BIV three plasmid gene transfer system contains the packaging construct,
the transfer vector construct, and the envelope expression construct. CMV, CMV immediate early promoter; Poly(A), SV40 polyadenylation signal;
MSD, major splice donor site; SA, splice acceptor site; Rev, BIV Rev; RRE, rev response element; UTR, untranslated region; GAG, deletion in gag
coding sequence; cPPT, central polypurine tract; MNDU3, a modified version of the myeloid proliferative sarcoma virus long terminal repeat U3 region
serving as an internal promoter driving eGFP; SIN, self-inactivating; SV40USE, SV40 polyadenylation signal upstream enhancer element; VSV-G,
vesicular stomatitis virus envelope glycoprotein G.
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Transduction of dividing and nondividing cells
We evaluated the capacity of the BIV vectors encoding
GFP to transduce dividing and nondividing cells. Vector
supernatants were assayed for RT activity. Equal
amounts of RT were used to transduce both dividing and
nondividing HeLa and Neuro-2A cells (Figs. 5 and 6). To
suppress cell division, cells were exposed to aphidicolin.
VSV-G pseudotyped MLV vector served as a control to
confirm the status of cell division. As expected, VSV-G
pseudotyped MLV vector efficiently transduced both di-
viding HeLa and Neuro-2A cells (Figs. 5B and 6B), but not
the aphidicolin-treated cells (Figs. 5E and 6E). In con-
trast, BIV vector efficiently transduced both nondividing
HeLa and Neuro-2A cells with the minimal BIV vector at
relatively high efficiencies (Figs. 5F and 6F). Therefore
the vectors generated from the minimal transfer vector
and the minimized packaging constructs were fully com-
petent to mediate transgene expression in both dividing
and nondividing cells.
To ensure that the modifications made to the packag-
ing construct did not compromise the vector transduction
efficiency, we did a side-by-side comparison of the vec-
tors generated either by pBH2 or by pBH2M2RRE6. We
found that pBH2 and pBH2M2RRE6 produced equivalent
amounts of vector particles as indicated by RT assay
(data not shown). Further, the same amount of RT-con-
taining vectors generated from these two packaging con-
structs transduced both dividing and nondividing HeLa
cells at equivalent efficiency (Fig. 7), suggesting that the
accessory genes vif and vpw are dispensable for BIV
vector-mediated gene expression in vitro.
Transduction of human primary cells
To examine the ability of the minimal BIV vector to
transduce primary cells, we transduced human primary
skeletal muscle cells treated with and without aphidico-
lin. MLV vector was used to confirm the status of cell
division. As expected, MLV efficiently transduced the
dividing primary cells (Fig. 8B), but did not score any
significant transduction in the nondividing cells (Fig. 8E).
In contrast, the BIV vector efficiently transduced both
dividing and nondividing primary cells (Figs. 8C and 8F),
confirming that the significant modification to the BIV
transfer vector and packaging constructs did not affect
the ability of the BIV vector to transduce both dividing
and nondividing human primary cells. Together, these
data suggest that accessory genes vif and vpw are
dispensable for BIV vector-mediated gene expression in
vitro. These data also confirmed that RRE6 is sufficient
for BIV RRE-mediated nuclear export of viral BIV RNA.
DISCUSSION
A lentiviral vector system based on BIV has been
reported (Berkowitz et al., 2001b). Initial testing sug-
gested that these vectors were able to transduce both
dividing and nondividing cells in vitro. Moreover, BIV
vectors efficiently transduced mouse retinal cells in vivo
and expressed GFP for the 5-month duration of the study
(Takahashi et al., 2002). However, limited knowledge of
BIV has made it difficult to develop an advanced version
of a BIV-based gene transfer system. Significant homol-
ogy between the BIV packaging and transfer vector con-
structs existed in the previous system (Berkowitz et al.,
FIG. 4. Titration of BIV nonconcentrated vectors encoding eGFP.
Cf2Th cells (4  105/per well) were transduced with 2 ml medium
containing Mock (A); 500 l of vectors (B); 250 l of vectors (C); 100 l
of vectors (D); and 50 l of vectors (E). Forty-eight hours posttransduc-
tion, the transduced cells were analyzed for eGFP expression by flow
cytometry. The number in the panels represents the percentage of
eGFP-positive cells. The experiment was repeated three times with
similar results.
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2001b). This was due in part to the fact that BIV packag-
ing signal sequence and the BIV RRE had not been
identified. Large portions of BIV gag and env coding
sequence remained in the transfer vector and a large
portion of env sequence remained in the packaging con-
struct. Lentiviral packaging signal sequences usually
extend into the gag coding region, although to different
degrees depending upon the lentivirus (Lever et al., 1989;
Aldovini and Young, 1990; Clavel and Orenstein, 1990;
Luban and Goff, 1994; Johnston et al., 1999). The early
generation BIV transfer vector was designed to contain
509 bp of gag sequence and 778 bp of env sequence to
ensure incorporation of the packaging signal and RRE,
respectively (Berkowitz et al., 2001b). In this study, we
were able to reduce the gag sequence to 104 bp without
affecting transduction efficiency of the vector (Fig. 3).
Lentiviruses contain instability sequences (INS) found
in gag, pol, env, and RRE (Luciw, 1996). To overcome this
disadvantage, lentiviruses have evolved a unique mech-
anism that utilizes a Rev protein that binds to an RRE
sequence to efficiently export viral genomic RNA and
singly spliced mRNA out of the nucleus (Schwartz et al.,
1992; Luciw, 1996; Cullen, 1998). Although BIV Rev coding
regions (two exons) have been identified (Oberste et al.,
1993), the precise location of BIV RRE had not been
mapped. In the current study, we identified a 312-bp
FIG. 5. Flow cytometry analysis of BIV vector-mediated eGFP expression in dividing and nondividing HeLa cells. (A, B, and C) Dividing cells. (D, E, and
F) Aphidicolin-treated cells. Cells were then transduced with either Mock (A and D), MLV vector (B and E), or BIV vector (C and F), respectively. The number
in the panels represents the percentage of eGFP-positive cells and is the mean of triplicate samples. SD refers to the standard deviation. The experiment
was performed three times with similar results.
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sequence which contains the RRE (Fig. 2). Removal of
this 312-bp sequence from the transfer vector rendered
the vector particles defective, as indicated by their in-
ability to transduce cells (data not shown).
By shortening the packaging signal sequence in the
vector construct and the RRE in the vector and packaging
constructs, we effectively reduced homologies between
these two constructs. Furthermore, we have inactivated
the regulatory gene tat in the packaging construct, as it
is not needed for the self-inactivating vector (Zufferey et
al., 1998; Deglon et al., 2000; Berkowitz et al., 2001b).
BIV has four predicted accessory genes, vif, vpw, vpy,
and tmx. The biological functions of these accessory
genes in the BIV lifecycle and pathogenesis have not yet
been delineated. Moreover, these accessory genes
share no significant homology with the accessory genes
found in other lentiviruses (Garvey et al., 1990; Gonda et
al., 1994). We truncated vif and vpw in the packaging
construct without affecting packaging function, suggest-
ing they are dispensable for gene transfer. The BIV vec-
tors generated from our minimized constructs are fully
functional, suggesting the modifications made to the
transfer vector construct, as well as the modifications
made to the packaging construct, did not affect the per-
formance of the vectors.
One of the major concerns with clinical applications of
lentivirus-based gene transfer systems is the potential
risk of generating replication competent lentiviruses
(RCL). It has been suggested that the potential risk exists
within HIV as well as other lentivirus-based systems (Wu
FIG. 6. Flow cytometry analysis of BIV vector mediated eGFP expression in dividing and nondividing Neuro2A cells. (A, B, and C) Dividing cells. (D, E,
and F) Aphidicolin-treated cells. Cells were then transduced with either Mock (A and D), MLV vector (B and E), or BIV vector (C and F), respectively. The
number in the panels represents the percentage of eGFP-positive cells and is the mean of triplicate samples. SD refers to the standard deviation. The
experiment was performed three times with similar results.
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et al., 1997; Buchschacher and Wong-Staal, 2000; Trono,
2000). Several strategies are being employed to mini-
mize the risk of generating RCL. The strategies utilized in
these studies include separating the vector system com-
ponents into multiple plasmids and minimizing the se-
quence homologies among the plasmids. The three-
plasmid system described here could also be separated
into four plasmids by expressing Rev in a different con-
struct (Dull et al., 1998). Alternatively, dividing the gag/pol
coding sequence into two plasmids should presumably
provide a safer lentivirus-based gene transfer system
(Wu et al., 1997, 2000). Finally, recoding gag/pol in the
FIG. 7. Flow cytometry analysis of BIV vector-mediated eGFP expression in dividing and nondividing HeLa cells. Dividing cells (A, B, C, and D) and
nondividing cells (E, F, G and H) transduced with either Mock (A and E), MLV vector (B and F), BIV vector generated from the parental packaging
construct pBH2 (C and G), or BIV vector generated from the minimized packaging construct pBH2M2RRE6 (D and H). The number in the panels
represents the percentage of eGFP-positive cells and is the mean of triplicate samples. SD refers to the standard deviation. The experiment was
performed three times with similar results.
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packaging construct significantly reduces the homology
between the packaging and the transfer vector con-
structs (Kotsopoulou et al., 2000; Wagner et al., 2000).
Although homologies still exist in the BIV-based system,
the identification of BIV packaging sequence and RRE
and modifications we made to the BIV-based gene trans-
fer system in this article should serve as a first step to
the generation of an efficient and safer BIV-based vector
system for human gene therapy.
MATERIALS AND METHODS
Plasmid construction
The transfer vector pBIVminivec was derived from
pBC4MGppt, which has previously been described
(Berkowitz et al., 2001b). To facilitate the cloning, the
entire BIV transfer vector coding sequence was cloned
into the expression plasmid pBS II KS (Stratagene, La
Jolla, CA) by digesting pBC4MGppt with BspMI and ligat-
ing to pBS II KS previously digested with HincII as a
blunt-end ligation to create the plasmid pBv. The plasmid
pBv was digested with BglII and EcoNI, Klenow treated,
and re-ligated to remove a 297-bp fragment of the gag
gene to create the plasmid pBvG, which contained
212-bp Gag coding sequence. Due to the lack of unique
and convenient restriction sites immediately following
the eGFP reporter gene, a unique PstI site was incorpo-
rated using the primers WPRE5 (5GAGCTGTACAAGTA-
AAGCGGCCAACCCTCCTGCAGAAACTCCTTTGGG-3)
and WPRE3 (5GGAACAAAAGCTGGGTACCGGGCCC-
FIG. 8. Flow cytometry analysis of BIV vector-mediated eGFP expression in dividing and nondividing primary human skeletal muscle cells. (A, B,
and C) Dividing cells. (D, E, and F) Aphidicolin-treated cells. Cells were transduced with either Mock (A and D), MLV vector (B and E), or BIV vector
(C and F), respectively. The number in the panels represents the percentage of eGFP-positive cells and is the mean of triplicate samples. SD refers
to the standard deviation. The experiment was performed three times with similar results.
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CCCC-3) to create the plasmid pBvGPstI. The wood-
chuck hepatitis posttranscriptional regulatory element
was then cloned into the backbone, pBvPstI, which was
previously digested with Pst1, treated with Klenow, and
ligated to the PRE fragment to create the plasmid
pBvGPRE. The plasmid pBvGPRE was further modi-
fied by removing all of the putative RRE, which is about
778 bp in the original BIV transfer vector (Berkowitz et al.,
2001b), and replacing it with a 312-bp fragment of the
RRE. First, the plasmid pBvGPRE was digested with
KasI and BbvCI. This region was then PCR amplified with
the primers RRE1 (5GTTGGCGCCCAACGTGGGGCTC-
GAGTAAGAGAG-3), RRE2 (5AGATCTGAATTCTAAGT-
GACCTATTTC-3), RRE3 (5GAATTCAGATCTTATGG-
GAATGAAAGACC-3), and RRE4 (5AACTGCTGAGGG-
CGGGACCGCATCTGG-3). RRE1 and RRE2 amplified
upstream of the putative RRE and primers RRE3 and
RRE4 amplified downstream of the putative RRE. The
products were then mixed in equal molar ratios and
amplified with primers RRE1 and RRE4. The final product
incorporated the KasI and BbvCI sites, deleting the entire
putative RRE. Furthermore, there were unique EcoRI and
BglII sites incorporated to create junction sites between
primers RRE2 and RRE3 for annealing of the final prod-
uct, but primarily for subsequent cloning of various re-
gions of the RRE. This PCR strategy created the plasmid
pBvRRE. The putative RRE was then PCR amplified with
seven sets of primers in various regions all encoding a 5
EcoRI site and a 3 BglII site to be cloned into the
backbone, pBvRRE. Once created, each fragment was
digested with EcoRI and BglII and cloned as described
above (Table 1). The final construct created was
pBIVminivec containing RRE6. The entire pBIVminivec
was then subjected to DNA sequencing to confirm the
integrity of the construct. The pBIVminivec was used for
all experiments in this article unless indicated otherwise.
To further delete the remaining 212-bp Gag coding
sequence in the pBIVminivec, the construct pBvRRE
was used as the template to make deletions in the gag
sequence to determine the location of the packaging
signal. The construct pBvRRE, which was described
above, was used to delete 184 bp of GAG by digesting
with ClaI and HindIII, treating with Klenow, and then
re-ligating. This cloning strategy resulted in a construct
containing 28 bp of Gag coding sequence, creating the
plasmid pBv28RRE. Next we created a vector construct
containing 54 bp of gag sequence. First, the template
pBvRRE was digested with KasI and EcoRI and alkaline
phosphatase treated. Gag coding region was amplified
using the primers NRS1 (5AACAGTTGGCGCCCAACGT-
GGGGCTC-3), NRS2 (5ATGCATCACGTGGGGTGTCAC-
CCTAACCTTACGAA-3), NRS3 (5CACGTGATGCATCGA-
TCTAAAAGACAGATTGGC-3), and NRS4 (5CATAA-
GATCTGAATTCAATGATCTAAGTG-3). NRS1 and NRS2
were used to amplify the 5 region of the Gag start codon
(ATG) to base-pair 54 of Gag. NRS3 and NRS4 amplified
3 of the stop codon of Gag through the BIV cPPT. The
products were then mixed in equal molar ratios and
amplified with primers NRS1 and NRS4. The final product
incorporated the KasI and EcoRI sites, deleting the last
158 bp of Gag within the template, resulting in a con-
struct containing 54 bp of Gag coding sequence. Further-
more, there were unique NsiI and PmlI sites incorporated
to create junction sites between primers NRS2 and NRS3
for annealing and screening of the final product. This
PCR strategy created the plasmid pBv54RRE. The same
PCR strategy was implemented to create the construct
pBv104RRE. NRS1 and NRS4 were used as external
primers and the new internal primers are NRS32 (5AT-
GCATCACGTGATTCTAATGGCCCATTGAAGATTC-3) and
NRS33 (5CACGTGATGCATCGATCTAAAAGACAGATTG-
GC-3). NRS1 and NRS32 were used to amplify the 5
region of the Gag start codon (ATG) to base-pair 104 of
Gag. NRS33 and NRS4 amplified 3 of the stop codon of
Gag through the BIV cPPT. The products were then
mixed in equal molar ratios and amplified with NRS1 and
NRS4. The final product incorporated the KasI and EcoRI
sites, deleting the last 108 bp of Gag within the template
pBv104RRE. As described above, there were unique
NsiI and PmlI sites incorporated to create junction sites
between NRS32 and NRS33 for annealing and screening
of the final product. Finally, all three constructs,
pBv28RRE, pBv54RRE, and pBv104RRE, were di-
gested with EcoRI and BglII, alkaline phosphatase
treated, and then the minimal RRE6, as described above,
was cloned in as an EcoRI and BglII fragment to create
the plasmids pBv28, pBv54, and pBv104, respectively. All
these transfer vector constructs were subjected to DNA
sequencing to confirm the integrity of the construct. To
generate the transfer vector construct with RRE at the
reverse orientation, pBv104 was digested with EcoRI and
BqlII to cut out the RRE6. Both fragments were then
blunt-ended and the RRE6 was cloned back at the re-
verse orientation by ligating the two fragments, creating
pBv104ERR.
The packaging construct pBH2M2RRE6 was derived
from the previously described construct pBH2 (Berkowitz
et al., 2001b). First, primers were constructed to delete
some of the 5 untranslated leader sequence without
affecting the MSD site. This region was PCR amplified
with primers pBH2delpac2F (5CATGTTGCATTG-3) and
pBH2delpac2R (5GGTTCTCCGGAGTTCGAGACTGTTG-
3), using pBH2 as the template. The pBH2 plasmid and
the PCR product were digested with SpeI and BspEI and
then ligated to create pBH2UTR. The next step was to
inactivate the tat gene by mutating the start codon of
exon 1 to a stop codon. The SalI fragment from
pBH2UTR encoding the first exon of tat was subcloned
into pUC19 (New England BioLabs, Beverly, MA). The
subclone was then amplified with primers pBH2deltatF
(5CCACCCAAGGTCCGGGCTAATTGCCACAATCTATG-
3) and pBH2deltatR (5CCACCCAAGGTCCGGGCTAATT-
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GCCACAATCTATG-3) using the Quickchange Site Di-
rected Mutagenesis kit (Stratagene) to create the plas-
mid pUC19tat. pUC19tat was then digested with SalI
and cloned back into pBH2UTRSalI to create the plas-
mid pBH2UTRtat. pBH2UTRtat was then digested
with EcoRV and NotI and subcloned into pBSII KS
(Stratagene) to truncate vif and vpw by inserting in-frame
stop codons 3 to the end of the pol reading frame. The
resulting plasmid created was pBSII KSpol. The sub-
clone was then amplified using the primers StopWF
(5GAGTTCGTGAGGCAGACTGAATAGAGCATGACCG-
CGTGCG-3) and StopWR (5CGCACGCGGTCATGCTC-
TATTCAGTCTGCCTCACGAACTC-3) using the Quick-
change Site Directed Mutagenesis kit to create the plas-
mid pBSII KSSTOPW. PBSII KSSTOPW was then
digested with EcoRV and NotI and cloned back into
pBH2UTRtat to create the plasmid pBH2M2. pBH2M2
was PCR amplified with the primers pBH2RRE5 (5ACG-
GCTAGCGCGCGACCATTTAGTGC-3) and pBH2RRE3
(5CATGTCTGCTCG-3) to remove all of the putative RRE.
The pBH2M2 backbone and the PCR product were di-
gested with NheI and XbaI and ligated to create the
plasmid pBH2M2RRE. Last, pBH2M2RRE was di-
gested with XbaI and Klenow treated. The RRE6 fragment
containing the mapped RRE6, as described above, was
digested with EcoRI and BglII, Klenow treated, and li-
gated into the pBH2M2RRE to create the final construct
pBH2M2RRE6. The packaging construct was then sub-
jected to DNA sequencing to confirm the integrity of the
construct.
The pVSV-G plasmid contains the vesicular stomatitis
virus glycoprotein and has previously been described
(Burns et al., 1993).
Cell lines and culture conditions
293T cells and HeLa cells were cultured in Dulbecco’s
modified Eagle’s medium (BRL Life Technology, Rock-
ville, MD) supplemented with 10% heat-inactivated fetal
bovine serum (FBS) (Hyclone, Salt Lake City, UT), 50 IU
penicillin/ml, 50 g streptomycin/ml, and 2 mm L-glu-
tamine (Complete DMEM). Cf2Th cells, a cell line derived
from canine thymus, was obtained from American Type
Tissue Collection (ATCC) (Manassas, VA). Cf2Th cells
were cultured in the same medium as that for 293T
except with 20% FBS. Mouse neuronal and amoeboid
stem cells (Neuro-2A) were also obtained from ATCC.
Neuro-2A cells were cultured in minimal essential me-
dium (BRL Life Technology) supplemented with 10%
heat-inactivated fetal bovine serum, 50 IU penicillin/ml,
50 g streptomycin/ml, 1.0 mM sodium pyruvate, 2 mM
L-glutamine, 1.5 g/L sodium bicarbonate, and 0.1 mM
nonessential amino acids. Human primary skeletal mus-
cle cells (SkMC) were obtained from Clonetics (San
Diego, CA). SkMC cells were cultured in SkBM basal
media with the SkGM bullet kit containing 0.1% human
epidermal growth factor, 1% insulin, 5% BSA, 5% fetuin,
1% gentamicin-amphotericin B, and 0.5 M dexametha-
sone. Cell lines were maintained at 37°C in a humidified
incubator with 5% CO2.
Viral vector production
In this article, all the vectors (unless indicated other-
wise) were generated with cotransfection of 293T cells
with pBH2M2RRE6 (packaging construct), BIV transfer
vector construct, and VSV-G expression construct. 293T
cells were seeded at a density of 10  106 into 150-mm
dishes overnight. The following day the medium was
aspirated and replaced with fresh complete DMEM. The
293T cells were transfected 4 h later using the Profection
mammalian transfection system calcium phosphate co-
precipitation method (Promega, Madison, WI). Typically,
45 g of the transfer vector, 45 g of the packaging
construct, and 13.5 g of the VSV-G plasmid were used
for each dish. After 24 h, the medium was aspirated and
replaced with fresh complete DMEM. Viral supernatant
was harvested at 48 h posttransfection, centrifuged at
2000 rpm for 10 min to clear cell debris, and stored
frozen in aliquots at 80°C. Generation of VSV-G
pseudotyped MLV vector encoding eGFP was described
previously (Roe et al., 1993; Liu et al., 1996; Gallardo et
al., 1997). To measure the amount of vector particles
shed into the medium, the medium is cleared of cellular
debris by low-speed centrifugation; then 10 l is lysed
and analyzed for RT activity using a commercial kit
(Roche Molecular Biochemicals, Indianapolis, IN).
Transduction
To transduce dividing cells, 1 105 cells were seeded
per well into six-well dishes. After 24 h, the medium was
aspirated and 2 ml of viral supernatant containing me-
dium was added to the cells. Protamine sulfate (Sigma,
St. Louis, MO) was then added to the wells at a final
concentration of 8 g/ml. Cells were then maintained at
37°C in a humidified incubator with 5% CO2 for 3 h. After
3 h, viral supernatant was aspirated and replaced with
fresh medium and incubated for 48 h at 37°C in a
humidified incubator with 5% CO2. To transduce nondi-
viding cells, 1  105 cells were seeded per well into
six-well dishes. After 24 h, aphidicolin was then added to
a final concentration of 4 g/ml (except for the human
primary cells where the concentration was reduced to 2
g/ml aphidicolin due to the toxicity). Sixteen hours post-
treatment with aphidicolin, the medium was aspirated
and 2 ml of viral supernatant containing medium was
added to the cells in the presence of aphidicolin. Prota-
mine sulfate was then added to the wells at a final
concentration of 8 g/ml. Cells were maintained at 37°C
in a humidified incubator with 5% CO2 for 3 h. Viral
supernatant was then aspirated and replaced with fresh
medium containing aphidocolin at a final concentration
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of 2 g/ml (except for the human primary cells where the
concentration was reduced to 1 g/ml aphidicolin) and
then incubated for 48 h at 37°C in a humidified incubator
with 5% CO2.
Flow cytometry analysis
For analysis of eGFP expression, the medium was
aspirated from the wells. The cells were then rinsed with
2 ml phosphate-buffered saline (PBS). The PBS was then
aspirated and the cells were trypsinized, washed, and
resuspended in PBS containing 5% heat-inactivated fetal
bovine serum. The cells were analyzed for eGFP expres-
sion on a FACS Calibur (Becton–Dickinson Biosciences).
Vector titer
To determine the vector titer, Cf2Th cells (4  105
cells/per well) were transduced with 2 ml medium con-
taining different amounts of viral vectors in six-well
dishes in the presence of protamine sulfate. After 3 h,
viral supernatant was aspirated and replaced with fresh
medium and incubated for 48 h at 37°C in a humidified
incubator with 5% CO2. EGFP expression was then ana-
lyzed by flow cytometry analysis. The vector titer was
calculated as follows: titer (transducing units/ml)  per-
centage of the positive cells  4  105 cells  dilution
factor.
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